Dare Bioscience Inc (DARE): Next-Year EPS Estimate 47.02%
As of 2026-08-26, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 47.02%. Featured in 2 EPS revision reports, most recently on 2026-04-20.
On 2026-08-18, analyst consensus for DARE's next-year EPS growth shifted from 55.54% to 47.02% — a negative change of 8.52 percentage points. The revised estimate has been sustained across 8 subsequent trading sessions. Current-year growth is projected at 34.72%.
What's Driving This
DARE’s rise is not tied to an EPS upgrade; on 2026-08-18 analysts actually lowered next-year growth estimates from 55.54% to 47.02%. Headlines cite a $6.0 million registered direct offering and a Phase 2 trial start for DARE-HPV, but neither clearly explains the move. No earnings beat, contract win, or guidance raise appears in recent news, so the upward trend lacks a clear fundamental catalyst.
Generated 2026-08-25 from news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 47.02%
- EPS growth this year
- 34.72%
- EPS next quarter (est)
- -$0.14
- Last price
- $0.78
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-26 | 47.02% | 34.72% | -$0.14 | $0.78 |
| 2026-08-25 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-24 | 47.02% | 34.72% | -$0.14 | $0.80 |
| 2026-08-23 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-21 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-20 | 47.02% | 34.72% | -$0.14 | $0.81 |
| 2026-08-19 | 47.02% | 34.72% | -$0.14 | $0.82 |
| 2026-08-18 | 47.02% | 34.72% | -$0.14 | $0.77 |
| 2026-08-17 | 55.54% | 22.22% | -$0.18 | $0.81 |
| 2026-08-16 | 55.54% | 22.22% | -$0.18 | $0.93 |
| 2026-08-14 | 54.95% | 24.17% | -$0.16 | $0.93 |
| 2026-08-13 | 49.30% | 21.11% | -$0.30 | $1.37 |
| 2026-08-12 | 49.30% | 21.11% | -$0.30 | $1.44 |
| 2026-08-11 | 49.30% | 21.11% | -$0.30 | $1.44 |
| 2026-08-10 | 49.30% | 21.11% | -$0.30 | $1.36 |
| 2026-08-09 | 49.30% | 21.11% | -$0.30 | $1.40 |
| 2026-08-07 | 49.30% | 21.11% | -$0.30 | $1.40 |
| 2026-08-06 | 49.30% | 21.11% | -$0.30 | $1.33 |
| 2026-08-05 | 49.30% | 21.11% | -$0.30 | $1.34 |
| 2026-08-04 | 49.30% | 21.11% | -$0.30 | $1.34 |
| 2026-08-03 | 49.30% | 21.11% | -$0.30 | $1.28 |
| 2026-08-02 | 49.30% | 21.11% | -$0.30 | $1.22 |
| 2026-07-31 | 49.30% | 21.11% | -$0.30 | $1.22 |
| 2026-07-30 | 49.30% | 21.11% | -$0.30 | $1.24 |
| 2026-07-29 | 49.30% | 21.11% | -$0.30 | $1.16 |
| 2026-07-28 | 49.30% | 21.11% | -$0.30 | $1.18 |
| 2026-07-27 | 49.30% | 21.11% | -$0.30 | $1.32 |
| 2026-07-26 | 49.30% | 21.11% | -$0.30 | $1.28 |
| 2026-07-24 | 49.30% | 21.11% | -$0.30 | $1.28 |
| 2026-07-23 | 49.30% | 21.11% | -$0.30 | $1.26 |
Reports Featuring DARE
Recent News
- Dare Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswire
- Dare Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesGlobeNewswire
- Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...GuruFocus.com
- Dare Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To ExpectGuruFocus.com
Screen Performance
Aggregate stats across all 2015 tickers our top-EPS-revision screen has flagged over the past 147 days.
- Median return since detection
- +3.0%
- % of tickers in the green
- 56%
- Median return on winners
- +20.0%
- Large revisions captured
- 1609
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Dare Bioscience Inc's next-year EPS growth estimate?▾
As of 2026-08-26, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 47.02%, based on analyst consensus.
When was the latest EPS estimate revision for DARE?▾
The most recent revision occurred on 2026-08-18, when analysts adjusted the next-year EPS growth estimate from 55.54% to 47.02%.
What sector and industry does Dare Bioscience Inc belong to?▾
Dare Bioscience Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. DARE appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Dare Bioscience Inc (DARE) appears here because it was detected by our daily top-EPS-revision-performer screen.